BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 11788979)

  • 41. Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods.
    O'Brien BJ; Briggs AH
    Stat Methods Med Res; 2002 Dec; 11(6):455-68. PubMed ID: 12516984
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-Effectiveness of Four Parenting Programs and Bibliotherapy for Parents of Children with Conduct Problems.
    Sampaio F; Enebrink P; Mihalopoulos C; Feldman I
    J Ment Health Policy Econ; 2016 Dec; 19(4):201-212. PubMed ID: 27991419
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Optimal public rationing and price response.
    Grassi S; Ma CT
    J Health Econ; 2011 Dec; 30(6):1197-206. PubMed ID: 21974868
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Optimisation versus certainty: understanding the issue of heterogeneity in economic evaluation.
    Stevens W; Normand C
    Soc Sci Med; 2004 Jan; 58(2):315-20. PubMed ID: 14604617
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Decision makers' views on health care objectives and budget constraints: results from a pilot study.
    Al MJ; Feenstra T; Brouwer WB
    Health Policy; 2004 Oct; 70(1):33-48. PubMed ID: 15312708
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The cost and efficiency of public and private health care facilities in Ogun State, Nigeria.
    Wouters A
    Health Econ; 1993 Apr; 2(1):31-42. PubMed ID: 8269045
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ramsey waits: allocating public health service resources when there is rationing by waiting.
    Gravelle H; Siciliani L
    J Health Econ; 2008 Sep; 27(5):1143-54. PubMed ID: 18468707
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Incorporating model uncertainty in cost-effectiveness analysis: a Bayesian model averaging approach.
    Negrín MA; Vázquez-Polo FJ
    J Health Econ; 2008 Sep; 27(5):1250-9. PubMed ID: 18490067
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Economic and Policy Analytic Approaches to Inform the Acceleration of HIV Prevention in the United States: Future Directions for the Field.
    Martin EG; Rosenberg ES; Holtgrave DR
    AIDS Educ Prev; 2018 Jun; 30(3):199-207. PubMed ID: 29969310
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Methods of comparative economic evaluations of therapies and for rational allocation of resources across sectors of health care systems - introduction, advantages, risks].
    Wasem J; Hessel F; Kerim-Sade C
    Psychiatr Prax; 2001 Jul; 28 Suppl 1():S12-20. PubMed ID: 11533902
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-effectiveness in ambulatory care: alternative approaches.
    Angus DE; Auer L; Cloutier JE; Albert T
    J Ambul Care Manage; 1995 Jan; 18(1):29-38. PubMed ID: 10139344
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Implicit valuation of a blood-exclusion decision.
    Kaplan EH
    Med Decis Making; 1999; 19(2):207-13. PubMed ID: 10231084
    [TBL] [Abstract][Full Text] [Related]  

  • 53. How to develop cost-conscious guidelines.
    Eccles M; Mason J
    Health Technol Assess; 2001; 5(16):1-69. PubMed ID: 11427188
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Patients' views of explicit rationing: what are the implications for health service decision-making?
    Devlin N; Appleby J; Parkin D
    J Health Serv Res Policy; 2003 Jul; 8(3):183-6. PubMed ID: 12869346
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Objectives, Budgets, Thresholds, and Opportunity Costs-A Health Economics Approach: An ISPOR Special Task Force Report [4].
    Danzon PM; Drummond MF; Towse A; Pauly MV
    Value Health; 2018 Feb; 21(2):140-145. PubMed ID: 29477391
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Optimal investment in a portfolio of HIV prevention programs.
    Zaric GS; Brandeau ML
    Med Decis Making; 2001; 21(5):391-408. PubMed ID: 11575489
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Indirect costs and cost-effectiveness analysis.
    Ernst R
    Value Health; 2006; 9(4):253-61. PubMed ID: 16903995
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In defence of societal sovereignty: a comment on Nyman 'the inclusion of survivor consumption in CUA'.
    Richardson JR; Olsen JA
    Health Econ; 2006 Mar; 15(3):311-3; discussion 319-22. PubMed ID: 16389655
    [TBL] [Abstract][Full Text] [Related]  

  • 59. On the decision rules of cost-effectiveness analysis.
    Johannesson M; Weinstein MC
    J Health Econ; 1993 Dec; 12(4):459-67. PubMed ID: 10131756
    [No Abstract]   [Full Text] [Related]  

  • 60. The cost-utility analysis of adult male circumcision for prevention of heterosexual acquisition of HIV in men in sub-Saharan Africa: a probabilistic decision model.
    Uthman OA; Popoola TA; Yahaya I; Uthman MM; Aremu O
    Value Health; 2011 Jan; 14(1):70-9. PubMed ID: 21211488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.